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Phar m ac eut ic a l  produc t s  - 
c om parat ive pr ic e levels  in  
33 European c ount r ies in  
2005 
In the framework of the joint Eurostat–OECD Purchasing Power Parity (PPP) 
Programme, surveys on prices of goods and services are carried out by 
National Statistical Institutes (NSIs). 37 countries are currently participating in 
the surveys co-ordinated by Eurostat1. The OECD co-ordinates the surveys 
for the 12 non-European OECD Member States. These spatial price surveys 
are corner stones of the work resulting in annual volume comparisons of the 
National Accounts aggregates: Gross Domestic Product (GDP) and its main 
components. This article provides results of the pharmaceutical products price 
survey carried out in November 2005 for 33 countries.
Chart 1: Price level indices for pharmaceutical products, EU25=100 
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1
 These are the 27 EU Member States,  the 3 Candidate Countries Croatia, the former Yugoslav 
Republic of Macedonia (MK; see METHODOLOGICAL NOTES) and Turkey, the 3 EFTA 
countries Iceland, Norway and Switzerland and 4 more Western Balkan Countries Albania, 
Bosnia-Herzegovina, Montenegro and Serbia. In this article, however, the data of the latter 4 
countries are not yet presented. 
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Pharmaceutical products – the survey 2005 
Expenditure on pharmaceutical products forms on 
average, for the 33 countries presented here, 1.5% of 
GDP. Expenditure is incurred by households as well as 
by governments. For households, the share of 
pharmaceutical products in total final expenditure is 
1.3%. 
Price data for in total 181 different pharmaceutical 
products were collected in November 2005, as part of a 
more general survey on health goods and services. The 
prices collected represent the full market price of a 
product. In many instances, only part of the price of a 
product is paid by households, while the remaining part 
is covered by government through social security 
schemes. In this survey the total price was collected, i.e. 
the sum of the share of the price paid by a household 
and the share of the price paid by the government. That 
means that the price level indices shown here are not a 
reflection of what households pay out of their "own 
pocket" but of total costs of pharmaceuticals to society, 
including the parts covered by private health insurance 
schemes on behalf of households. 
To establish the list of products to be priced, two 
aspects are important. First and most important, 
products have to be found that are comparable across 
countries. For pharmaceuticals this is relatively easy, as 
they can be identified among other things by active 
substance. Secondly, for each country in the 
comparison the list of products should be sufficiently 
representative, i.e. reflecting the product consumers 
actually buy. For this purpose, first a list of best-selling 
drugs was compiled on the basis of detailed sales 
information from a large number of countries. To obtain 
the highest possible representativity the products were 
taken from the top of the best-sellers list2. 
Furthermore, a distinction was made between "original" 
drugs, which are those that are or have been covered 
by a patent, and "generic" drugs, which are copies of 
original drugs that are produced after the patent has 
expired. The list of 181 products that were to be priced 
consisted of about 75% original drugs and 25% generic 
drugs. This ratio was one of the findings from the 
analysis of the best-sellers lists. 
In many countries prices were collected from centralised 
information systems from ministries of health, 
supervising bodies for the pharmaceutical industry or 
associations of pharmacists. In other countries, prices 
were collected by visiting pharmacies. 
 
Comparative price levels of pharmaceutical products 
Chart 1 shows the price level indices (PLIs) for 
pharmaceuticals. The PLI for a country indicates its 
price level compared to the average price level of the 
25 countries that made up the EU in 2005. The level of 
uncertainty associated with the underlying price and 
other data, and the methods used for compiling PPPs 
and PLIs imply that strict ranking of countries is not 
advisable (see also the methodological notes). In chart 
1, the countries are therefore divided into six groups. 
The top group consists of two countries that have 
significantly higher price levels than the others: Iceland 
and Switzerland, with price levels being 60% and 87% 
higher than the EU25 average respectively. In the 
second group of most expensive countries (where price 
levels are between 15% and 30% higher than the EU25 
average) we find Denmark, Germany, Ireland, Italy and 
Norway.  
Seven countries have price levels between 0% and 
15% higher than the EU25 average: Belgium, Cyprus, 
Luxembourg, Malta, the Netherlands, Austria and 
Finland. Another five countries have price levels 
between 0% and 15% lower than the EU25 average: 
France, Portugal, Slovenia, Sweden and the United 
Kingdom. 
Then there is a large group of countries with price 
levels between 68 and 80% of the EU25 average: 
Bulgaria, Czech Republic, Estonia, Greece, Spain 
Latvia, Lithuania, Hungary, Poland, Romania, Slovakia, 
Croatia and Turkey. It is especially remarkable how 
even the price distribution is among the new Member 
States and Acceding and Candidate countries. From 
the new Member States, only Cyprus, Slovenia and 
Malta are closer to price levels of the pre-2004 Member 
States. The lowest price levels are found in the Former 
Yugoslav Republic of Macedonia at 58% of the EU25 
average. 
́́́́́́́́́́́ 
 
2
 Eurostat would like to thank pharmacist Mrs. G. Schuh , Nittel, Germany, for help in establishing the item list. 
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Price dispersion of pharmaceutical products 
The level of price dispersion across countries can be 
measured by the coefficient of variation of the PLIs, 
which is defined as the standard deviation as 
percentage of the average. A high coefficient of 
variation indicates a high price dispersion. Table 1 
shows the coefficients of variation for all 
pharmaceuticals, for all original pharmaceuticals and 
for all generic pharmaceuticals. It shows that prices 
for original drugs are less dispersed than those of 
generic drugs. This is probably due to the greater 
heterogeneity of generic drugs compared to originals 
and to the fact that generic drugs are often produced 
for domestic markets only. 
 
Table 1: Coefficients of variation of the PLIs 
All pharmaceutical products Original drugs Generic drugs 
27.9 25.8 42.8 
 
  
 
 ESSENTIA L  INFORMA TION – METHODOL OGICA L  NOTES 
The data in this publication are produced by the Eurostat-OECD 
Purchasing Power Parity (PPP) programme. The full methodology 
used in the programme is described in the Eurostat-OECD 
Methodological manual on purchasing power parities which is 
available free of charge from the Eurostat website on 
http://epp.eurostat.ec.europa.eu/portal/page?_pageid=1073,465872
59&_dad=portal&_schema=PORTAL&p_product_code=KS-BE-06-
002 
In their simplest form PPPs are nothing more than price relatives 
that show the ratio of the prices in national currencies of the same 
good or service in different countries. For example, if the price of a 
hamburger in France is 2.84 euros and in the United States it is 2.20 
dollars, the PPP for hamburgers between France and the United 
States is 2.84 euros to 2.20 dollars or 1.29 euros to the dollar. In 
other words, for every dollar spent on hamburgers in the United 
States, 1.29 euros would have to be spent in France in order to 
obtain the same quantity and quality – or volume – of hamburgers. 
Comparative price levels as presented in this publication are the 
ratios of PPPs to exchange rates. They provide a measure of the 
differences in price levels between countries by indicating for a given 
product group the number of units of common currency needed to 
buy the same volume of the product group or aggregate in each 
country. Price level indices (PLIs) provide a comparison of the 
countries’ price levels with respect to the European Union average: if 
the price level index is higher than 100, the country concerned is 
relatively expensive compared to the EU average and vice versa. 
Price level indices are not intended to rank countries strictly. In fact, 
they only provide an indication of the comparative order of 
magnitude of the price level in one country in relation to others, 
particularly when countries are clustered around a very narrow 
range of outcomes. The degree of uncertainty associated with the 
basic price data and the methods used for compiling PPPs, may 
affect in such a case the minor differences between the PLIs and 
result in differences in ranking which are not statistically or 
economically significant. It is, therefore, preferable to use these 
indices to divide countries into groups of a comparable level, as 
done in this article. 
The main use of PPPs is to convert expenditures (including GDP) of 
different countries into real expenditures (and real GDP). Real 
expenditures are valued at a uniform price level and so reflect only 
differences in the volumes purchased in countries. PPP and real 
expenditures provide the price and volume measures required for 
international comparisons. 
Country codes: MK is a provisional code which does not prejudge in 
any way the definitive nomenclature for this country, which will be 
agreed following the conclusion of negotiations currently taking 
place on this subject at the United Nations. 
  
Further information: 
Data: 
EUROSTAT Website/Data/Economy and finance/Prices/Purchasing power parities 
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